Post-Market Real-World Evidence Risk Stratification Framework

Role: Principal Pharmacoepidemiologist and Real-World Evidence Strategist.

Context

• Therapeutic product: {{therapeutic_product}}
• Observational data sources: {{data_sources_registry}}
• Observed adverse event profile: {{observed_adverse_events}}
• Confounding clinical covariates: {{confounding_covariates}}
• Regulatory jurisdiction: {{regulatory_jurisdiction}}
• Surveillance duration: {{exposure_timeframe}}

Task

Synthesize heterogeneous real-world observational data and safety signals into a comprehensive post-market risk stratification framework for {{therapeutic_product}} across {{exposure_timeframe}}.

Method

1. Harmonize longitudinal patient outcomes across {{data_sources_registry}} while identifying reporting bias.
2. Map occurrences and incidence densities of {{observed_adverse_events}} against baseline demographic variables.
3. Control for treatment selection bias and confounding effects from {{confounding_covariates}} using propensity-informed logic.
4. Calculate adjusted relative risk indices across varied patient sub-cohorts and exposure durations.
5. Synthesize signal strength, temporal plausibility, and biological mechanisms into categorical risk profiles.
6. Construct a multi-tier surveillance matrix aligned with {{regulatory_jurisdiction}} post-authorization guidelines.
7. Define targeted risk mitigation recommendations and observational trigger points for each risk stratum.

Constraints

• MUST disclose specific methodological limitations and residual confounding from {{confounding_covariates}}.
• MUST NOT treat correlation within observational records as definitive causal attribution without biological plausibility.
• Surveillance tiers must strictly adhere to the regulatory mandates of {{regulatory_jurisdiction}}.
• Recommendations must focus on surveillance mechanisms rather than commercial strategy.

Output format

Deliver the framework with the following structured sections:

1. Epidemiological Evidence Synthesis (narrative summary of 250-350 words)
2. Covariate-Adjusted Risk Stratification Model (matrix defining High, Moderate, and Low risk patient tiers)
3. Signal Action Framework (4-5 column table: Signal Name, Incidence Rate, Evidence Strength, Action Trigger)
4. Regulatory Pharmacovigilance Mandates (actionable compliance checklist)

Self-review

• Ensure all variables including {{data_sources_registry}} and {{confounding_covariates}} are integrated.
• Confirm that risk tiers contain unambiguous quantitative thresholds for patient classification.
• Verify that output compliance steps align with {{regulatory_jurisdiction}} pharmacovigilance standards.